{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:06:46Z","timestamp":1776816406037,"version":"3.51.2"},"reference-count":24,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2005,6,7]],"date-time":"2005-06-07T00:00:00Z","timestamp":1118102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold>To determine hepatitis C virus (HCV) prevalence among injecting drug users (IDUs) receiving opioid replacement therapy in a referred office setting, and assess potential needs for hepatitis C treatment and care.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold>Data were collected on 178\u2003IDUs receiving opioid replacement therapy who underwent clinical assessment between January 2002 and June 2003. Standard clinic protocols included HCV and hepatitis B virus (HBV) serology, liver biochemistry and HCV RNA analysis for patients with a positive HCV antibody and normal alanine aminotransferase (ALT) levels.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold>HCV prevalence was 75.3%, similar for males (75.5%) and females (74.4%), and increased with age from 60.8% for 19\u201330\u2003years to 93.9% above 40\u2003years. Among patients with HCV antibodies and no prior HCV antiviral therapy (<jats:italic>n<\/jats:italic>\u2003=\u2003130), 53.1% had normal ALT levels and 25.4% were HCV\u2010RNA negative. Older patients were more likely to have normal ALT levels (<jats:italic>P\u2003<\/jats:italic>=\u20030.02), and be HCV\u2010RNA negative (<jats:italic>P\u2003<\/jats:italic>=\u20030.02). Younger patients were more likely to have been HBV vaccinated (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001), however, were less likely to have either vaccine or natural immunity (<jats:italic>P\u2003<\/jats:italic>=\u20030.006). Of 97\u2003patients with probable chronic HCV infection, 58\u2003patients met pre\u2010liver biopsy criteria for HCV treatment, 34\u2003had relative contraindications to treatment and 6\u2003had been referred for treatment assessment.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold>Clinical characterization in a setting of high HCV prevalence has enabled the differentiation of patients into groups with no evidence of HCV viraemia, with chronic HCV infection, and those most appropriate for HCV treatment referral. These clinical assessments along with appropriate referral should be instituted in drug dependency treatment settings.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2005.03882.x","type":"journal-article","created":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T09:30:04Z","timestamp":1282037404000},"page":"1082-1086","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy"],"prefix":"10.1111","volume":"20","author":[{"given":"RICHARD","family":"HALLINAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANDREW","family":"BYRNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JANAKI","family":"AMIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GREGORY J","family":"DORE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyg101"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7156.433"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2002.02730.x"},{"key":"e_1_2_6_5_2","volume-title":"HIV\/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2002.","author":"NCHECR.","year":"2002"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-12-200212170-00009"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2002.tb04333.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290311"},{"issue":"1","key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff LB","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ewjm.172.1.16"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199802001-00004"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.2001.tb00550.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08435-0"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50019"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36129"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00807-2"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00668-1"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00436.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.27831"},{"issue":"3","key":"e_1_2_6_20_2","first-page":"137","article-title":"Coinfection by hepatitis B virus and hepatitis C virus","volume":"3","author":"Pontisso P","year":"1998","journal-title":"Antivir. Ther."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb02979.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.1997.tb01664.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50031"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(02)00010-8"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25882"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2005.03882.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2005.03882.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T18:18:22Z","timestamp":1740421102000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2005.03882.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1440-1746.2005.03882.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2005.03882.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,7]]},"assertion":[{"value":"2005-06-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}